Vir Biotechnology is a San Francisco-based company focused on finding innovative solutions to unmet needs in infectious disease. The foundation’s 2016 investment in Vir is supporting the development of affordable and accessible HIV and TB prophylactic vaccine programs. Our 2022 reinvestment is focused on advancing innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a “vaccinal effect” for the treatment of HIV and prevention of malaria.
Investment Date: December 2016
Reinvestment Date: January 2022